US FDA Discourages Off-Label Guidance Suits as Challenges To Entire Approval Authority

 
• By Michael McCaughan
  
The FDA said BIO/PhRMA marketing principles were not as specific as its policy. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Marketing & Advertising

More from Legal & IP